CTX-2026

CTX-2026 is a fully human antibody that targets and binds to CD277. CTX-2026 demonstrates anti-tumor effects in ovarian tumor models , and CTX-2026 is utilized in oncology research focused on immune receptor targeting, tumor microenvironment modulation, and antibody-based targeting of CD277-expressing cellular systems.

Methods：Cells were treated with 1 μg/mL CTX-2026 for 12 hours and 6 days respectively. The cytotoxic function of Vγ9Vδ2 T cells and the survival of CD45⁺ T cells were detected.
Results：Treatment with 1 μg/mL CTX-2026 for 12 h remodeled the cytotoxic activity of Vγ9Vδ2 T cells against BTN3A1-positive OVCAR3 cells and primary high-grade serous ovarian cancer cells. Intervention at the same concentration for 6 days protected residual CD45⁺ T cells [1].

Methods：Mice bearing NY-OVCAR3 tumors were intraperitoneally injected with CTX-2026 at a dose of 5 mg/kg once every three days for 15 consecutive days, and tumor growth was observed.
Results：CTX-2026 inhibited the growth of NY-OVCAR3 tumors in mice [1].

Human

Monoclonal

Unconjugated